Tempest Therapeutics Future Growth
Future criteria checks 0/6
Tempest Therapeutics's earnings are forecast to decline at 17.2% per annum while its annual revenue is expected to grow at 66.6% per year. EPS is expected to decline by 5.3% per annum.
Key information
-17.2%
Earnings growth rate
-5.3%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 66.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 21 Jun 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -58 | -64 | -48 | 5 |
| 12/31/2025 | N/A | -42 | -42 | -32 | 6 |
| 12/31/2024 | N/A | -33 | -31 | -21 | 6 |
| 3/31/2024 | N/A | -30 | -27 | -26 | N/A |
| 12/31/2023 | N/A | -29 | -28 | -27 | N/A |
| 9/30/2023 | N/A | -31 | -28 | -28 | N/A |
| 6/30/2023 | N/A | -33 | -31 | -30 | N/A |
| 3/31/2023 | N/A | -35 | -33 | -32 | N/A |
| 12/31/2022 | N/A | -36 | -32 | -31 | N/A |
| 9/30/2022 | N/A | -34 | -33 | -33 | N/A |
| 6/30/2022 | N/A | -34 | -35 | -35 | N/A |
| 3/31/2022 | N/A | -31 | -27 | -27 | N/A |
| 12/31/2021 | N/A | -28 | -26 | -26 | N/A |
| 9/30/2021 | N/A | -25 | -22 | -22 | N/A |
| 6/30/2021 | N/A | -22 | -15 | -15 | N/A |
| 3/31/2021 | N/A | -20 | -20 | -20 | N/A |
| 12/31/2020 | N/A | -19 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TPST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TPST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TPST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TPST is forecast to have no revenue next year.
High Growth Revenue: TPST is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TPST's Return on Equity is forecast to be high in 3 years time